What happens if you stop Compounded tirzepatide or Wegovy?

Wegovy's label includes a trial that stopped the drug on purpose; Compounded tirzepatide has no FDA label at all, which is a difference in what is known rather than in what happens. On Wegovy's label, the people randomly assigned to stop gained 6.9% of body weight over the following 11 months while those who carried on lost 7.9% more. That figure belongs to Wegovy's trial, so this page does not apply it to Compounded tirzepatide.

Is Compounded tirzepatide or Wegovy better for weight loss?

Only Wegovy has a trial figure recorded here: 14.9% average weight loss, from its own label trial. Compounded tirzepatide has none on this site — a compounded preparation has no trial of its own, so the two cannot be compared on effect and this page does not pick one on it.

Can you switch between Compounded tirzepatide and Wegovy?

They are different molecules, so this is a change of medication rather than of brand, and the one you move to is started on its own dosing schedule.

← All providers and medications

Compounded tirzepatide vs Wegovy (semaglutide injection)

Verdict

Wegovy is the better choice of the two, winning on regulatory and complaint risk and approved product or compounded copy (halfrx score 6.9 against 1.8).

Computed from the stored fields, so it moves when a price does. Nothing here is written by hand or by a model.

Which is cheaper, Compounded tirzepatide or Wegovy (semaglutide injection)?

Compounded tirzepatide is $199–$359 a month all-in, the range its sellers here charge, oldest read 2026-09-13; Wegovy (semaglutide injection) is $199–$399, read from its own page on 2026-09-22. Every axis below is computed from stored fields rather than written by hand, so the comparison moves when a price does. They were last checked on 2026-09-13 and 2026-09-22. Flags recorded here: Compounded tirzepatide — not FDA approved, manufacturer lawsuit, supply risk. Wegovy (semaglutide injection) is an FDA-approved product and Compounded tirzepatide is a compounded copy made under the pharmacy-compounding exemption, which is a legal status rather than a quality claim. The published formula scores them 1.8 and 6.9 out of 10, arithmetic over the same stored fields rather than an editor's preference. Cost here is scored on what a patient pays once titrated, never on the entry price, because an introductory rate covers the months before anybody has reached the dose they stay on.

Head to head

Compounded tirzepatide against Wegovy (semaglutide injection), one row per axis, with the side that wins each axis marked.
What decides it	Compounded tirzepatide $199–$359/mo	Wegovy $199–$399/mo
Entry priceBoth start at $199/mo.	tied	tied
Regulatory and complaint riskCompounded tirzepatide: 3 serious flags. Wegovy (semaglutide injection): none.	—	✓ better here
Approved product or compounded copyWegovy (semaglutide injection) supplies an FDA-approved product; Compounded tirzepatide supplies a compounded preparation, which the FDA does not review for safety, efficacy or quality and which can stop shipping if its pharmacy is enjoined.	—	✓ better here

Compounded tirzepatide publishes no page halfrx will send you toGo to Wegovy ↗

What separates these two, price aside

These are different molecules — tirzepatide against semaglutide — so this is a comparison of two treatments, not of two prices for one.

503A/503B compounding pharmacies

Compounded tirzepatide

1.8

$199–$359/mo all-in

checked 2026-09-13 — no maintenance-dose price

Not FDA approvedCompounding legal riskManufacturer lawsuitSupply risk

Novo Nordisk

Wegovy (semaglutide injection)

6.9

$199–$399/mo all-in

verified 2026-09-22

Boxed warning

Compounded tirzepatide

Pros

+Access to tirzepatide, the most effective molecule, at $199–$359/mo against Zepbound's $1,086 list.[1]
+Vial dosing allows finer titration than branded pens.[1]

Cons

−Not FDA approved — no review of safety, efficacy or manufacturing quality.[1]
−Eli Lilly has active lawsuits against compounded tirzepatide sellers, including Henry Meds. A ruling against your provider ends your supply.[2]
−The tirzepatide shortage that legally permitted mass compounding has been resolved, so the category now operates on contested legal ground.[2]
−Zepbound vials through LillyDirect start at $299/mo — the branded gap is far smaller than it was, which weakens the only argument for compounding.[1]

Sources

Wegovy (semaglutide injection)

Pros

+One flat $349 across every standard dose from 0.25 to 2.4 mg — no dose-escalation penalty and no refill deadline attached, unlike Lilly's conditional pricing on Zepbound.[1]
+New patients pay $199 for the first two fills through 31 December 2026 — the first two of the four titration months.[2]
+Approved for cardiovascular risk reduction, not only weight — the strongest insurance-coverage argument in the category.[1]
+The longest real-world safety record of any modern weight-loss GLP-1.[1]
+Commercially insured, the savings card can bring it to $25 a month, capped at $100 of savings per month.[2]

Cons

−$1,349 monthly list price without insurance or the self-pay program.[1]
−Weaker than tirzepatide where the two were tested head to head: in SURMOUNT-5, weight fell 13.7% on semaglutide against 20.2% on tirzepatide over 72 weeks.[6]
−A month is one box of four weekly pens, so a year takes 13 boxes, not 12: $4,537 at $349 rather than the $4,188 that 'per month' implies.[1]
−The new high dose, Wegovy HD 7.2 mg, sits outside the flat price at $399.[1]
−Weekly injection, refrigerated storage, GI side effects during titration, and weight regain after stopping is the documented norm.[3]

Sources

Wegovy side effects →Wegovy dosage →

Comparisons are computed from the fields on each card, not written by hand or by a model, so they change when the data does. Information only, not medical advice. halfrx may earn a commission from some links, which never changes what a comparison says.

Everything on Compounded tirzepatide

Everything on Wegovy

The registers and documents behind both sides

Two cards compared on the same checks. These are the registers those checks were run against, and the FDA's own pages where either side is a compounded product.

Compounding and the FDA: questions and answers — What a compounded drug is, and what the FDA does and does not review before it is sold.
Medications containing semaglutide marketed for type 2 diabetes or weight loss, FDA — The FDA's own notice on compounded semaglutide and what it has not evaluated.

Compounded tirzepatide against Wegovy, answered

What happens if you stop Compounded tirzepatide or Wegovy?: Wegovy's label includes a trial that stopped the drug on purpose; Compounded tirzepatide has no FDA label at all, which is a difference in what is known rather than in what happens. On Wegovy's label, the people randomly assigned to stop gained 6.9% of body weight over the following 11 months while those who carried on lost 7.9% more. That figure belongs to Wegovy's trial, so this page does not apply it to Compounded tirzepatide.
Is Compounded tirzepatide or Wegovy better for weight loss?: Only Wegovy has a trial figure recorded here: 14.9% average weight loss, from its own label trial. Compounded tirzepatide has none on this site — a compounded preparation has no trial of its own, so the two cannot be compared on effect and this page does not pick one on it.
Which is cheaper, Compounded tirzepatide or Wegovy?: Both start at $199 a month. For Compounded tirzepatide ($199–$359) only a starting price is published, not one for the maintenance dose, so which costs less once titrated cannot be worked out here.
Can you switch between Compounded tirzepatide and Wegovy?: They are different molecules, so this is a change of medication rather than of brand, and the one you move to is started on its own dosing schedule.